CTLA4Ig Prevents Alloantibody Formation Following Nonhuman Primate Islet Transplantation Using the CD40-Specific Antibody 3A8
I.R. Badell(Emory University), Christian P. Larsen(Emory University Hospital), Minjung Song(Emory University), Kenneth Cardona(Emory University), Thomas C. Pearson(Emory Healthcare), Maria C. Russell(Emory University), J.A. Cano(Emory University), Elizabeth Strobert(Emory University), Allan D. Kirk(University of Calgary), A.P. Turner(Emory University), Mandy L. Ford(Emory Healthcare), José G. Ávila(Emory University), F. Leopardi(Emory Healthcare), Virginia Shaffer(Emory University)
Cited by 50
Related Papers
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Heterologous immunity provides a potent barrier to transplantation tolerance
|Journal of Clinical Investigation|2003|571
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
|American Journal of Transplantation|2010|566